Kurve strikes agreement with Dara BioSciences

Edited by the Laboratorytalk editorial team Mar 31, 2006

Kurve Technology has announced the signing of an agreement with development-stage pharmaceutical company Dara BioSciences (DBI)

DBI focuses on the treatment of metabolic diseases, central nervous system disorders and medical devices.

"We are impressed with the quality and flexibility of Kurve's technology platform and excited about the combining Kurve's drug delivery technology platform with Dara's pharmaceutical formulations," commented John Didsbury, executive vice president of Dara BioSciences.

"Dara Biosciences' research and development is the type of leading-edge pharmaceutical science for which our devices were developed," said Marc Giroux, chairman and chief executive officer of Kurve Technology.

"We are thrilled to be working with the innovative team at Dara." Incorporating patented Controlled Particle Dispersion and intelligent nasal drug delivery technologies, Kurve Technology's ViaNase electronic atomizer intranasally delivers topical, systemic and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices such as spray pumps.

ViaNase is the first nasal drug delivery device that saturates the entire nasal cavity, allowing delivery to the paranasal sinuses.

In addition, ViaNase limits peripheral deposition of pharmaceutical formulations into the lungs or stomach.

Kurve Technology's most recent device offering - ViaNase ID - incorporates drug pedigree confirmation, lock-out technology, and an electronic display to curb counterfeit drug use and abuse while improving patient compliance.